Latest News

Update on the diagnosis and management of SPMS



Click here to take the survey

There has been considerable uncertainty and confusion about the diagnosis of secondary-progressive multiple sclerosis (SPMS), which may stem in part from the MS Phenotype Group’s early efforts to define the clinical course of MS (Lublin et al. Neurology 2014; 83:278-286). In that paper, four sub-phenotypes of SPMS were described: those with active disease with disability progression (once considered to be transitional SPMS); active disease without disability progression (once considered RRMS); non-active disease with progression (once considered SPMS); and non-active disease without progression.

Read More

ACTRIMS-ECTRIMS 2020 HIGHLIGHTS – Special session on COVID-19


September 13 Edition
September 12 Edition
September 11 Edition

ACTRIMS/ECTRIMS 2020 concluded on September 26th with a special session on COVID-19. Presentations and posters attempted to clarify risk factors for COVID-19 in MS patients, and to address the question of whether disease-modifying therapies (DMT) – most specifically anti-CD20 therapies – affect the risk of acquiring SARS-CoV-2 infection or clinical outcomes of COVID-19. Data were provided by large multinational patient registries and individual MS centres.

Read More